Hims & Hers Health’s stock jumped more than 30% Monday morning after the health and wellness platform said it would offer compounded versions of popular GLP-1 drugs.
Hims & Hers Health says it will offer compounded GLP-1 drugs, despite FDA warnings
Read Next
- Mortgage rates tumble on tariffs, but housing costs still high
- MTS launches innovative Dealer-to-Client Ticket protocol
- Family offices are moving money out of the U.S. on tariff, economic fears
- YouTube announces Shorts editing features amid potential TikTok ban
- The Pound Outperforms Its Peers :: InvestMacro
- Trump’s 25% auto tariffs are in effect. What investors need to know
- Stellantis idles plants in Mexico and Canada due to tariffs
